Quantum BioPharma settles debt with shares
Analysis based on 12 articles · First reported Jul 20, 2026 · Last updated Jul 20, 2026
The debt settlement is a minor corporate action that reduces liabilities by issuing equity, which may dilute existing shareholders slightly. The impact on Quantum BioPharma's stock price is expected to be negligible given the small amount involved.
Quantum BioPharma Ltd. announced on July 20, 2026 that its board of directors approved the settlement of CAD$123,487.43 owed to arm's length creditors and insiders through the issuance of Class B subordinate voting shares. The deemed price per share is the lower of CAD$4.26 and the closing price on the Canadian Securities Exchange on the trading day prior to closing. The securities are not registered under the U.S. Securities Act and cannot be offered or sold in the United States absent registration or exemption. Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative, metabolic, and alcohol misuse disorders. Its subsidiary Lucid Psycheceuticals Inc. develops Lucid-MS for multiple sclerosis. The company also holds a 19.84% stake in Unbuzzd Wellness Inc. and receives royalties from unbuzzd sales.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard